Molecular Cross-Talk between Integrins and Cadherins Leads to a Loss of Vascular Barrier Integrity during SARS-CoV-2 Infection.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
25 04 2022
Historique:
received: 01 04 2022
revised: 20 04 2022
accepted: 22 04 2022
entrez: 28 5 2022
pubmed: 29 5 2022
medline: 1 6 2022
Statut: epublish

Résumé

The vascular barrier is heavily injured following SARS-CoV-2 infection and contributes enormously to life-threatening complications in COVID-19. This endothelial dysfunction is associated with the phlogistic phenomenon of cytokine storms, thrombotic complications, abnormal coagulation, hypoxemia, and multiple organ failure. The mechanisms surrounding COVID-19 associated endotheliitis have been widely attributed to ACE2-mediated pathways. However, integrins are emerging as possible receptor candidates for SARS-CoV-2, and their complex intracellular signaling events are essential for maintaining endothelial homeostasis. Here, we showed that the spike protein of SARS-CoV-2 depends on its RGD motif to drive barrier dysregulation by hijacking integrin αVβ3, expressed on human endothelial cells. This triggers the redistribution and internalization of major junction protein VE-Cadherin which leads to the barrier disruption phenotype. Both extracellular and intracellular inhibitors of integrin αVβ3 prevented these effects, similarly to the RGD-cyclic peptide compound Cilengitide, which suggests that the spike protein-through its RGD motif-binds to αVβ3 and elicits vascular leakage events. These findings support integrins as an additional receptor for SARS-CoV-2, particularly as integrin engagement can elucidate many of the adverse endothelial dysfunction events that stem from COVID-19.

Identifiants

pubmed: 35632633
pii: v14050891
doi: 10.3390/v14050891
pmc: PMC9143673
pii:
doi:

Substances chimiques

Cadherins 0
Integrin alphaVbeta3 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Front Cardiovasc Med. 2021 Jun 11;8:687783
pubmed: 34179146
Sci Rep. 2021 Oct 14;11(1):20398
pubmed: 34650161
J Biol Chem. 2010 Mar 5;285(10):7045-55
pubmed: 20048167
J Biol Chem. 2022 Mar;298(3):101695
pubmed: 35143839
Circ Res. 2019 Mar 15;124(6):891-903
pubmed: 30707047
JAMA. 2021 Feb 16;325(7):632-644
pubmed: 33475701
Life Sci. 2021 Nov 1;284:119881
pubmed: 34389403
Phys Chem Chem Phys. 2022 Apr 20;24(16):9123-9129
pubmed: 35395667
Mol Biol Cell. 2004 Jun;15(6):2943-53
pubmed: 15075376
Lancet Oncol. 2014 Sep;15(10):1100-8
pubmed: 25163906
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
J Biol Chem. 2005 Sep 9;280(36):31906-12
pubmed: 16027153
JACC Basic Transl Sci. 2021 Jan;6(1):1-8
pubmed: 33102950
Front Cell Infect Microbiol. 2022 Apr 29;12:892323
pubmed: 35619646
PLoS One. 2021 Jun 23;16(6):e0253347
pubmed: 34161337
Tissue Barriers. 2019;7(4):1685844
pubmed: 31690180
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
PLoS One. 2012;7(5):e37195
pubmed: 22606350
Nature. 2022 Feb;602(7898):671-675
pubmed: 35016199
J Biol Chem. 2003 May 23;278(21):19199-208
pubmed: 12626512

Auteurs

Danielle Nader (D)

Cardiovascular Infection Research Group, School of Pharmacy and Biomolecular Sciences (PBS), RCSI University of Medicine and Health Sciences, 123 St. Stephen's Green, D02 YN77 Dublin, Ireland.

Steve W Kerrigan (SW)

Cardiovascular Infection Research Group, School of Pharmacy and Biomolecular Sciences (PBS), RCSI University of Medicine and Health Sciences, 123 St. Stephen's Green, D02 YN77 Dublin, Ireland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH